Probiotics and Antibiotic Diarrhea

What the pooled trials measured

Antibiotic-associated diarrhea is a common side effect of antibiotic treatment, and researchers have tested whether co-administering probiotics can reduce how often it occurs. Two 2021 meta-analyses pooled randomized controlled trials in adults: one synthesized 42 trials with 11,305 participants, and the other combined 36 randomized placebo-controlled trials with 9,312 participants. Both used the incidence of antibiotic-associated diarrhea as the primary outcome they measured.^{[1], [2]}

Across both analyses, probiotics taken with antibiotics were associated with an approximately 37-38% lower risk of antibiotic-associated diarrhea relative to placebo or no probiotic (risk ratios near 0.62-0.63). These are pooled, population-level associations from trials using a range of probiotic strains and doses, not a result for any single product or regimen.^{[1], [2]}

Dose, species, and baseline risk

The association was not uniform. In subgroup analyses from the 42-trial systematic review, a higher dose of the same probiotic was linked to greater protection than a lower dose, and the benefit came mainly from lactobacillus and bifidobacteria species. The same review reported no difference in studies where participants had a low baseline risk of diarrhea, with significant risk reduction concentrated in moderate- or high-risk settings.^[1]

Both research teams noted that the optimal dose and duration of probiotics for this purpose remain undefined, so the subgroup signals describe where the effect appeared larger rather than establishing a specific recommended regimen.^[1]

Adverse events in the pooled data

The 36-trial meta-analysis also pooled adverse event rates and found no statistically significant increase in adverse events among adults taking probiotics compared with placebo (relative risk 1.00, 95% CI 0.87-1.14). The authors described early co-administration during antibiotic therapy as having a positive effect on preventing antibiotic-associated diarrhea in the adult populations studied.^[2]

Limitations

The overall quality of the evidence was graded as moderate, and the pooled trials varied widely in probiotic strain, dose, and timing, which limits how precisely any single regimen can be recommended. The protective association was not seen in populations at low baseline diarrhea risk, so results may not apply to lower-risk clinical scenarios.^{[1], [2]}

Both meta-analyses focused on adults; pooled adverse-event data showed no significant increase but do not establish safety for immunocompromised or critically ill people, and the findings are not medical advice.^[2]